We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Is the Induction of Insulin Production in Gut Stem Cells a Possible Treatment for Diabetes?

By LabMedica International staff writers
Posted on 19 Mar 2012
Abolishing the activity of the Foxo1 gene in mouse gut Neurog3+ progenitor cells caused these cells to differentiate into a type capable of producing fully active insulin.

Stem cell therapy to replace insulin producing pancreatic beta cells has been considered for treatment of type I diabetes. More...
However, such cells would not be under hormonal control and could produce dangerously high levels of insulin.

Another approach is to induce other types of normally occurring cells to manufacture the hormone. Investigators at Columbia University (New York, NY, USA) inadvertently revealed the potential of this technique when they used genetic engineering to abolish the activity of the mouse Foxo1gene in gut stem cells known as Neurog3+ progenitor cells.

The investigators reported in the March 11, 2012, issue of the journal Nature Genetics that Neurog3+ progenitors actually require active Foxo1 to prevent differentiation into insulin producing cells. Without Foxo1 the gut cells produced insulin that was released into the bloodstream where it worked as well as normal insulin. The gut cells produced insulin in sufficient quantity to nearly normalize blood glucose levels in otherwise diabetic mice.

“Our results show that it could be possible to regrow insulin-producing cells in the GI tracts of our pediatric and adult patients,” said senior author Dr. Domenico Accili, professor of medicine at Columbia University. “Nobody would have predicted this result. Many things could have happened after we knocked out Foxo1. In the pancreas, when we knock out Foxo1, nothing happens. So why does something happen in the gut? Why do we not get a cell that produces some other hormone? We do not yet know.”

“All these findings make us think that coaxing a patient's gut to make insulin-producing cells would be a better way to treat diabetes than therapies based on embryonic or induced pluripotent stem cells,” said Dr. Accili. “However, it is important to realize that a new treatment for type I diabetes needs to be just as safe as, and more effective than, insulin. We cannot test treatments that are risky just to remove the burden of daily injections. Insulin is not simple or perfect, but it works and it is safe.”

Related Links:

Columbia University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.